Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-3
Status: Recruiting
Location: See all (13) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age 18 years or older, of either sex;
• Acute ischemic stroke caused by occlusion of the basilar artery;
• Decide to undergo emergency endovascular treatment;
• Time from stroke onset to groin puncture within 24 hours;
• National Institutes of Health Stroke Scale (NIHSS) ≥ 10;
• Posterior circulation Alberta Stroke Program Early computed tomography score (pc-ASPECTS) ≥ 6;
• Signed informed consent from the patients or the legally authorized representatives.
Locations
Other Locations
China
Anyang People's Hospital
RECRUITING
Anyang
Capital Medical Univercity Xuanwu Hospital
RECRUITING
Beijing
People's Hospital of Linyi
RECRUITING
Linyi
Lishui Central Hospital
RECRUITING
Lishui
Nanyang Central Hospital
RECRUITING
Nanyang
Suzhou Municipal Hospital
RECRUITING
Suzhou
Taizhou enze Hospital
RECRUITING
Taizhou
Xianyang First People's Hospital
RECRUITING
Xianyang
The First Affiliated Hospital of Henan Medical University
RECRUITING
Xinxiang
People's Hospital of Yueqing
RECRUITING
Yueqing
Yuncheng Central Hospital
RECRUITING
Yuncheng
People's Hospital of Xihua
RECRUITING
Zhoukou
Zibo Central Hospital
RECRUITING
Zibo
Contact Information
Primary
Xunming Ji
jixm@ccmu.edu.cn
01083198962
Backup
Chuanjie Wu
wuchuanjie@ccmu.edu.cn
01083199439
Time Frame
Start Date:2026-04-22
Estimated Completion Date:2027-04-20
Participants
Target number of participants:348
Treatments
Experimental: Tocilizumab
Endovascular treatment combined with a 240mg tocilizumab injection once